dolutegravir + tenofovir alafenamide + emtricitabine

**Dolutegravir + tenofovir alafenamide + emtricitabine** is an oral fixed-dose, three-drug antiretroviral combination for treatment of HIV-1 infection. It contains dolutegravir 50 mg, an HIV-1 integrase strand-transfer inhibitor, plus emtricitabine 200 mg and tenofovir alafenamide 25 mg, nucleoside or nucleotide reverse-transcriptase inhibitors that inhibit viral DNA synthesis through intracellular active metabolites and chain termination. The product is supplied as a once-daily film-coated tablet and has been tentatively approved through the FDA PEPFAR pathway and listed by WHO Prequalification for HIV/AIDS treatment. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/215448PI.pdf))

Brand names

Tivicay + Descovy

Other names

DTG/TAF/FTCTAF/FTC + DTGdolutegravir + emtricitabine + tenofovir alafenamidedolutegravir + tenofovir alafenamide + emtricitabinedolutegravir/emtricitabine/tenofovir alafenamide